ALK inhibitor Xalkori, meanwhile, has been approved to treat ROS1-positive NSCLC since 2016 and made $283 million in the same period, split between that indication and ALK-mutated NSCLC and lymphoma.

Want to learn about a clinical trial targeting patients who have tumours with ALK or ROS1 gene alterations?' reads a recent tweet from @NovartisCancrUS, Novartis' Twitter channel dedicated to its ...

Despite solid data, the lack of high-value indications and no unique platform makes Nuvalent's valuation seem inflated; I ...

BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, ...

or ALK, ROS1 or RET genomic tumor aberrations. The National Medical Products Administration (NMPA) of China has approved sugemalimab for five indications: In combination with chemotherapy as first ...

Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.